U.S. Food and Drug Administration (FDA)

Investment thesis

The FDA does not provide grants, equity, or non-financial funding to external founders or startups. It is a regulatory enforcement and public health protection agency, not a venture fund or research funder. Its mission is to ensure the safety and efficacy of food, drugs, medical devices, and cosmetics, not to finance commercial development. Any interaction with the FDA is strictly compliance-driven, focused on meeting statutory requirements for market access rather than receiving financial support. The agency's role is to evaluate applications for approval or clearance, not to fund innovation. Founders seeking capital, grants, or research subsidies should look to agencies like the NIH, NSF, or SBIR programs, not the FDA. The FDA's 'funding' is limited to regulatory fees paid by industry for specific services, which are costs to the applicant, not revenue. There is no public programme for external financial support. The agency's budget is appropriated by Congress for its own operations, not distributed as grants to private entities. Therefore, the FDA is not a viable source of public funding for founders.

Value add

The FDA provides regulatory clarity and market access upon approval, which is valuable for commercialization. However, it offers no financial support, networks, or facilities. Fit verdict: The FDA is not a source of funding. Founder diligence script: 1. Confirm if you are seeking regulatory approval or funding. 2. If funding, identify agencies like NIH, NSF, or SBIR. 3. If regulatory, prepare for compliance costs and timelines.

Portfolio focus

The FDA does not have a portfolio of funded projects. It has a portfolio of approved products and regulated entities. Publicly available data includes lists of approved drugs, cleared devices, and warning letters. These reflect regulatory outcomes, not funding decisions. There is no 'portfolio' in the investment sense.